Document Detail


Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure.
MedLine Citation:
PMID:  17440445     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Duchenne muscular dystrophy (DMD) is a fatal disease of striated muscle deterioration resulting from the loss of the cytoskeletal protein dystrophin. Most patients develop significant cardiomyopathy, with heart failure being the second leading cause of death in DMD. Compared with the extensive studies on skeletal muscle defects and potential therapy in DMD, very little attention has been directed at the increasing incidence of heart failure in DMD. Here we show that a single systemic injection of recombinant adeno-associated virus (rAAV2/6) harboring micro-dystrophin leads to extensive cardiac transduction, with micro-dystrophin correctly localized at the periphery of the cardiac myocytes and functionally associated with the sarcolemmal membrane. Significantly, micro-dystrophin gene transfer corrected the baseline end-diastolic volume defect in the mdx mouse heart and prevented cardiac pump failure induced by dobutamine stress testing in vivo, although several parameters of systolic function were not corrected. These results demonstrate that systemic gene delivery of micro-dystrophin can restore ventricular distensibility and protect the mdx myocardium from pump dysfunction during adrenergic stimulation in vivo.
Authors:
DeWayne Townsend; Michael J Blankinship; James M Allen; Paul Gregorevic; Jeffrey S Chamberlain; Joseph M Metzger
Related Documents :
19374295 - A comparison of one-year outcome in adult patients with heart failure in two medical se...
15893215 - Doctors' use of euphemisms and their impact on patients' beliefs about health: an exper...
9505865 - Increased l-arginine transport in human erythrocytes in chronic heart failure.
11927785 - Difficult cases in heart failure: amiodarone lung injury: another heart failure mimic?
20417775 - First finite element model of the left ventricle with mitral valve: insights into ische...
1971585 - Cardiac adrenoceptors in the failing heart: effect of intervention.
Publication Detail:
Type:  Journal Article     Date:  2007-04-17
Journal Detail:
Title:  Molecular therapy : the journal of the American Society of Gene Therapy     Volume:  15     ISSN:  1525-0016     ISO Abbreviation:  Mol. Ther.     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-05-18     Completed Date:  2007-09-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100890581     Medline TA:  Mol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1086-92     Citation Subset:  IM    
Affiliation:
Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, USA. dtown@umich.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Agonists / toxicity
Animals
Blotting, Western
Cardiomyopathies / chemically induced,  therapy*
Dependovirus / genetics*
Dobutamine / toxicity
Dystrophin / genetics*,  metabolism
Fluorescent Antibody Technique
Gene Therapy / methods*
Genetic Vectors / administration & dosage,  genetics
Glycoproteins / metabolism
Mice
Mice, Inbred C57BL
Mice, Inbred mdx
Muscular Dystrophy, Duchenne / chemically induced,  therapy*
Myocardium / metabolism,  pathology
Chemical
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Dystrophin; 0/Glycoproteins; 34368-04-2/Dobutamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Transgene persistence and cell turnover in the diarthrodial joint: implications for gene therapy of ...
Next Document:  Cell lineage regulators in B and T cell development.